5-<3-(bis-4-methoxyphenyl)-hydroxymethyl>-phenoxy-levulinic acid | 169140-99-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 5-<3-(bis-4-methoxyphenyl)-hydroxymethyl>-phenoxy-levulinic acid
• 英文别名: 5-[3-[Hydroxy-bis(4-methoxyphenyl)methyl]phenoxy]-4-oxopentanoic acid
• CAS: 169140-99-2
• 化学式: C₂₆H₂₆O₇
• 分子量: 450.488
• InChiKey: QZEWGVUCEZYVBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  33
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-<3-(bis-4-methoxyphenyl)-hydroxymethyl>-phenoxy-levulinic acid 在 吡啶 、 4-二甲氨基吡啶 、 溶剂黄146 、 N,N'-二环己基碳二亚胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 5-{3-[Methoxy-bis-(4-methoxy-phenyl)-methyl]-phenoxy}-4-oxo-pentanoic acid (2R,3S,5R)-2-hydroxymethyl-5-{4-[2-(4-nitro-phenyl)-ethoxycarbonylamino]-2-oxo-2H-pyrimidin-1-yl}-tetrahydro-furan-3-yl ester
  参考文献：
  名称：

  寡核苷酸合成的组合保护基策略

  摘要：

  将描述新颖的5'-3'指导的DNA合成。连同对模型化合物的其他研究一起，建立了允许多选择脱保护的合成策略。这提供了产生具有不同序列特异性保护/功能化状态的寡核苷酸或产生可用于特定分子相互作用或识别实验的分子组合集的潜力。

  DOI：

  10.1016/0040-4020(96)00337-7
• 作为产物：
  描述：

  5-<3-(bis-4-methoxyphenyl)-hydroxymethyl>-phenoxy-levulinic acid methyl ester 在 甲醇 、 水 、 potassium carbonate 作用下， 反应 72.0h， 以96%的产率得到5-<3-(bis-4-methoxyphenyl)-hydroxymethyl>-phenoxy-levulinic acid
  参考文献：
  名称：

  A new colorimetric protecting group allowing deprotection under neutral conditions

  摘要：

  A 4,4'-dimethoxytrityl derivative of the levulinyl group has been developed for protection of nucleophilic functionalities such as hydroxyl groups by reaction of its symmetrical anhydride. It can rapidly be removed under mild conditions using a hydrazine-pyridinium acetate based buffer at near neutral pH. This protecting group can be detected with high sensitivity at 513 nm (epsilon = 78,600).

  DOI：

  10.1016/0040-4020(95)00228-z

文献信息

• [EN] ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS<br/>[FR] DÉRIVÉS D'ALBICIDINE, LEUR UTILISATION ET LEUR SYNTHÈSE
  申请人：TECH UNIVERSITÄT BERLIN

  公开号：WO2014125075A1

  公开（公告）日：2014-08-21

  The present invention relates to a antibiotically active compounds characterized by general formula (I), wherein X1, BB, BC, BD, BE and X2 are building blocks with D1, D2, D3, D4 or D5 being linkers which comprise carbon, sulphur, nitrogen, phosphor and/or oxygen atoms and which are covalently connecting the moities BA and BB, BB and BC, BC and BD, BD and BE and BE and BF, respectively, and wherein in particular the building block BC comprises an amino acid derivative. The invention relates further to said compounds for use in a method of treatment of diseases, in particular for use in a method of treatment of bacterial infections.

  本发明涉及一种抗生素活性化合物，其特征在于一般式（I），其中X1、BB、BC、BD、BE和X2是具有D1、D2、D3、D4或D5为连接物的构建块，该连接物包括碳、硫、氮、磷和/或氧原子，并以共价键连接BA和BB、BB和BC、BC和BD、BD和BE以及BE和BF的基团，特别是构建块BC包括氨基酸衍生物。该发明还涉及上述化合物用于治疗疾病的方法，特别是用于治疗细菌感染的方法。
• [EN] SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1<br/>[FR] SYNTHÈSE D'INHIBITEURS DE LA 11?-HYDROXYSTÉROÏDE DÉHYDROGÉNASE DE TYPE 1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010010150A1

  公开（公告）日：2010-01-28

  Disclosed are syntheses of 11β-HSD1 inhibitors and corresponding intermediates that are promising for the treatment of a variety of disease states including diabetes, metabolic syndrome, obesity, glucose intolerance, insulin resistance, hyperglycemia, hypertension, hypertension-related cardiovascular disorders, hyperlipidemia, deleterious gluco-corticoid effects on neuronal function (e.g. cognitive impairment, dementia, and/or depression), elevated intra-ocular pressure, various forms of bone disease (e.g., osteoporosis), tuberculosis, leprosy (Hansen's disease), psoriasis, and impaired wound healing (e.g., in patients that exhibit impaired glucose tolerance and/or type 2 diabetes).

  披露了合成11β-HSD1抑制剂及相应中间体的方法，这些方法对治疗包括糖尿病、代谢综合征、肥胖、葡萄糖耐量不良、胰岛素抵抗、高血糖、高血压、与高血压相关的心血管疾病、高脂血症、糖皮质激素对神经功能的有害影响（例如认知障碍、痴呆症和/或抑郁症）、眼内压升高、各种骨病（例如骨质疏松症）、结核病、麻风病（汉森病）、牛皮癣以及伤口愈合受损（例如在表现出糖耐量不良和/或2型糖尿病的患者中）等多种疾病状态具有前景。
• [EN] NOVEL AMINO ACID MOLECULE AND USES THEREOF<br/>[FR] NOUVELLE MOLÉCULE D'ACIDES AMINÉS ET SES UTILISATIONS
  申请人：CANADA INC 6570763

  公开号：WO2011134067A1

  公开（公告）日：2011-11-03

  There is provided novel amino acid molecules and processes for their preparation. There is also provided novel amino acid molecules and their use in processes for preparing the compounds that are useful for the synthesis of paclitaxel, and docetaxel, the anticancer drug.

  提供了新颖的氨基酸分子及其制备方法。还提供了新颖的氨基酸分子及其在制备对紫杉醇和多西紫杉醇这两种抗癌药物的合成有用化合物的过程中的应用。
• SEMI-SYNTHETIC ROUTE FOR THE PREPARATION OF PACLITAXEL, DOCETAXEL, AND 10-DEACETYLBACCATIN III FROM 9-DIHYDRO-13-ACETYLBACCATIN III
  申请人：LIU Jian

  公开号：US20070293687A1

  公开（公告）日：2007-12-20

  A novel semisynthetic route has been provided in the preparation of docetaxel and paclitaxel. This new process involves the conversion of 9-dihydro-13-acetylbaccatinIII to docetaxel and paclitaxel by the step of converting 9-dihydro-13-acetylbaccatin III into 7-O-triethylsilyl-9,10-diketobaccatin III, and adding docetaxel and paclitaxel side chain precursors, respectively, to form a new class of taxane intermediates, such as 7-O-triethylsilyl-9,10-diketodocetaxel and 7-O-triethylsilyl-9,10-diketopaclitaxeltaxel. These new intermediates then by a series reduction, acetylation of the 10-hydroxyl position for paclitaxel and finally deprotection to yield docetaxel and paclitaxel, the most important anti-cancer drugs.

  一种新的半合成路线已经提供在紫杉醇和紫杉醇的制备中。这个新的过程涉及将9-二氢-13-乙酰基紫杉醇III转化为紫杉醇和紫杉醇的步骤，即将9-二氢-13-乙酰基紫杉醇III转化为7-O-三乙基硅基-9,10-二酮紫杉醇III，并分别添加紫杉醇和紫杉醇的侧链前体，形成一类新的紫杉烷中间体，如7-O-三乙基硅基-9,10-二酮紫杉醇和7-O-三乙基硅基-9,10-二酮紫杉醇。然后通过一系列还原、对紫杉醇的10-羟基位置的乙酰化，最终去保护，得到紫杉醇和紫杉醇，这是最重要的抗癌药物。
• [EN] PROCESS FOR CONVERTING 9-DIHYDRO-13-ACETYLBACCATIN III INTO DOCETAXEL OR PACLITAXEL<br/>[FR] PROCÉDÉ DE CONVERSION DE LA 9-DIHYDRO-13-ACÉTYLBACCATINE III EN DOCÉTAXEL OU PACLITAXEL
  申请人：CANADA INC 6570763

  公开号：WO2009023967A1

  公开（公告）日：2009-02-26

  Processes for the preparation of docetaxel and paclitaxel or analogs from 9-dihydro-13-acetylbaccatin III via key intermediates (4), (5), (6), (6'), (8) and (8') or via intermediate (12) as well as processes for the preparation of said intermediates are disclosed. Said processes involve, in particular, oxidation of the hydroxy group at C-10, reaction with side chain precursors and intramolecular isomerisation of the oxo at C-10 to produce the 9-oxo isomer. Paclitaxel and docetaxel are useful in the treatment of cancer. Formulae (I), (II), (III).

  从9-二氢-13-乙酰基紫杉醇III经过关键中间体(4)、(5)、(6)、(6')、(8)和(8')或经过中间体(12)制备紫杉醇和多西紫杉醇或类似物的过程以及制备所述中间体的过程被披露。这些过程涉及特别是氧化C-10处的羟基、与侧链前体反应以及C-10处的酮的分子内异构化以产生9-酮异构体。紫杉醇和多西紫杉醇在癌症治疗中很有用。公式(I)、(II)、(III)。